Top Back to top

RACE, a severe aplastic anaemia trial, reaches its recruitment target of 200 patients


RACE is a prospective randomised multicenter study that compares standard immunosuppresive therapy (ATG+CsA) - horse Antithymocyte globuline (hATG) plus Cyclosporine A (CsA) - with or without Eltrombopag as front-line therapy for severe aplastic anaemia patients. The primary objective is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated aplastic anemia patients.

This trial started in July 2015, and in April 2019 reached its objective of 200 randomised patients in 28 participating sites in 6 countries. The team is now preparing to analyse the primary endpoint data. The results will be disclosed later this year and will hopefully lead to improved treatment of patients suffering from aplastic anaemia.

EBMT TV interviewed the two RACE trial Coordinating Investigators, Prof. Antonio Risitano and Prof. RĂ©gis Peffault de Latour, who explain the aims and characteristics of the RACE trial. Sofie Terwel, EBMT Clinical Trial Coordinator, takes the opportunity to thank the principal investigators and their teams for their efforts and contribution to this landmark trial. She also thanks the grant givers for their collaboration in this trial.

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to